Chinese Study: Ecnoglutide Outperforms Semaglutide in Weight Loss by 35%
Sciwind Biosciences announced interim analysis results from its head-to-head study (SLIMMER-UP-SWITC...
Danish Zealand Pharma's Partner Drug Phase III Trial: Visceral Fat Reduced by 34%, Liver Fat by 63%
On June 7, Zealand Pharma announced that its partner Boehringer Ingelheim's glucagon/GLP-1 dual agon...
Amgen Reports New Results from Evolocumab Trial in the US: 25% Risk Reduction in Primary Endpoint
Amgen announced new overall and subgroup results from the Phase 3 VESALIUS-CV trial of Repatha (evol...
Germany's healthcare cost-cutting plan leads to 50% reduction in Eli Lilly's investment and Boehringer Ingelheim's suspension of €900 million project
Germany's federal government healthcare cost-cutting plan is having a direct impact on large pharmac...
Curium invests €32 million in France to build a prostate cancer radiopharmaceutical production line
Curium, a global leader in nuclear medicine, announced at the "Choose France" summit held in Versail...
Rakovina's R&D Spending Rises to 70% of Operating Expenses in Q1
Rakovina Therapeutics Inc. (RKV:TSX.V) reported its first-quarter financial results for the period e...
Altesa ASM Conference Presents Vapendavir Phase 2a Study
Altesa BioSciences announced clinical study results showing that its oral investigational rhinovirus...
US Cloudbreak's Phase III Pterygium Drug Completes Final Visit
Cloudbreak Pharma Inc. (Hong Kong Stock Exchange Code: 2592) announced that the Phase III clinical t...
Mabwell's 9MW5211 Receives NMPA Clinical Trial Approval for IBD in China
Shanghai, June 4, 2026 — Mabwell (688062.SH, 02493.HK) announced that its independently developed in...
Tunisia Achieves Local Production of Key Radiopharmaceutical for Prostate Cancer
With support from the International Atomic Energy Agency (IAEA), Tunisia has achieved local producti...